A long list of drug targets are deemed undruggable, beyond the reach of current drug discovery technologies. A few companies hope to soon cross the β-catenin transcription factor off that list.
FOG-001 targets the β-catenin–TCF interaction, a previously "undruggable" target, offering new hope for desmoid tumor treatment. Early clinical trials show FOG-001 leads to significant tumor shrinkage ...
Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in ...
HOUSTON, Feb. 16, 2021 /PRNewswire/ — Iterion Therapeutics, Inc. ("Iterion"), a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has ...
Volume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by ...
Volume 11, Issue 26 of Oncotarget reported that in this study the authors studied the differences in mi RNA expression between sporadic and FAP-associated Desmoid tumors using microarray confirmed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results